老年人糖尿病患者药物治疗方案的药物经济学对比分析被引量：1

导出

摘要目的对比分析两种药物治疗方案在老年人糖尿病治疗中的效果与进行成本效益分析。方法应用药物经济学的成本-效益分析(CBA)方法比较评价两种糖尿病治疗药物治疗方案的应用情况。结果两种治疗药物的有效性分别为96%、98%,两种方案所得的成本效益分析差异无显著性(P>0.05)。结论两种药物治疗方案在治疗老年人糖尿病均能获得较满意的效果,成本相差不大,均可选用。

作者袁晓英

机构地区河南省安阳市人民医院

出处《中国现代药物应用》 2010年第7期215-215,共1页 Chinese Journal of Modern Drug Application

关键词糖尿病药物治疗方案成本-效益分析老年临床研究

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献2

1卜一珊,曲莎,刘伟,徐彦贵.2型糖尿病不同口服药物治疗方案的经济学评价[J].中国医院药学杂志,2006,26(3):319-320. 被引量：9
2胡善联,陈文,ANNE MANS Lieven,候晓欣.厄贝沙坦治疗中国高血压性2型糖尿病伴有微蛋白尿症患者的成本-效果分析[J].中国药房,2005,16(3):191-194. 被引量：9

二级参考文献17

1Parving HH,Lehnert H,Brochner MJ, et al..The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J ].N Engl J Med,2001,345:910.
2Lewis EJ,Hunsicker LG,Clarke WR,et al .Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2diabetes[ J ]. N Engl J Med , 2001,345:851.
3World Health Organization. Life tables for 191 countries. World mortality in 2000 [EB/OL]..http:∥www3.who.int/whosis/life tables/lifetables.cfm? path=evidence, life tables&language = english. 2002.
4Stehouwer CD, Gall MA, Twisk JW, et al.Increased urinary albumin excretion, endothelial dysfunction, and chronic low- grade inflammation in type 2 diabetes:progressive, interrelated, and independently associated with risk of death [J ]. Diabetes, 2002,51:1 157.
5Rodby RA, Chiou CF, Borenstein J, et al..The costeffectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy[J].Clin Ther, 2003, 25:2 103.
6Palmer AJ,Annemans L, Roze S, et al.An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; costeffectiveness of Irbesartan in Diabetic Nephropathy Trial(IDNT) in the Belgian, and French settings[J ]..Nephrol Dial Transplant, 2003,18:2 059.
7Adler AI, Stevens R J, Manley SE, et al..Development and progression of nephropathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study(UKPDS 64) [J ]. Kidney Int, 2003,63:225.
8Walters DP,Gatling W,Houston AC,et al .Mortality in diabetic subjects:an eleven- year follow- up of a community - based population[J ].Diabet Med, 1994,11:968.?A
9Eastman RC, Javitt JC, Herman WH, et al.Model of complications of NIDDM.I.Model construction and assumptions[J ]..Diabetes Care, 1997a,20(5):725.
10Eastman RC, Javitt JC, Herman WH, et al.Model of complications of NIDDM.Ⅱ.Analysis of the health benefits and cost - effectiveness of treating NIDDM with the goal of normoglycemia[J].. Diabetes Care,1997b, 20(5):735.